SynthesisBioMed research international2015
Short-Term Effects of Verapamil and Diltiazem in the Treatment of No Reflow Phenomenon: A Meta-Analysis of Randomized Controlled Trials.
Synthesis in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 4 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- The predictive value of laboratory parameters for no-reflow phenomenon in patients with ST-elevation myocardial infarction following primary percutaneous coronary intervention: A meta-analysis.Clinical cardiology · 2024Pooled it
- Nicorandil prior to primary percutaneous coronary intervention improves clinical outcomes in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials.Drug design, development and therapy · 2019Pooled it
- The predictors of no reflow phenomenon after percutaneous coronary intervention in patients with ST elevation myocardial infarction: A meta-analysis.Indian heart journal · 2018Pooled it
- Advances in Coronary No-Reflow Phenomenon-a Contemporary Review.Current atherosclerosis reports · 2018Pooled it
- Detection of Microvascular Failure After Thrombectomy Directly in the Angio-Suite Using Parametric Color Coding.Clinical neuroradiology · 2026Article
- A practical approach to the management of percutaneous coronary intervention complications.Frontiers in cardiovascular medicine · 2026Review
- Pharmacological and Interventional Prevention and Treatment of Microvascular Obstruction Following Primary PCI in STEMI.Journal of cardiovascular development and disease · 2025Review
- Advances in Pathophysiology and Novel Therapeutic Strategies for Coronary No-Reflow Phenomenon.Biomedicines · 2025Review
- Efficacy and safety of Traditional Chinese Medicine injections for no-reflow or slow flow in patients with acute coronary syndrome after percutaneous coronary intervention: a systematic review and network meta-analysis.Frontiers in cardiovascular medicine · 2025Review
- Effects of intracoronary administration of small doses of nicorandil and verapamil on blood pressure and heart rate.American heart journal plus : cardiology research and practice · 2024Article
- Article
- Pathophysiology and Treatment of the No-Reflow Phenomenon in ST-Segment Elevation Myocardial Infarction: Focus on Low-Dose Fibrinolysis during Primary Percutaneous Intervention.Reviews in cardiovascular medicine · 2023Review
- Coronary No-Reflow after Primary Percutaneous Coronary Intervention-Current Knowledge on Pathophysiology, Diagnosis, Clinical Impact and Therapy.Journal of clinical medicine · 2023Review
- Pathophysiology, Diagnosis, and Management of Coronary No-Reflow Phenomenon.The International journal of angiology : official publication of the International College of Angiology, Inc · 2022Article
- "No-Reflow" Phenomenon: A Contemporary Review.Journal of clinical medicine · 2022Review
- Predictive value of C-reactive protein/albumin ratio for no-reflow in patients with non-ST-elevation myocardial infarction.Journal of cardiovascular and thoracic research · 2022Article
- Pathophysiology, Diagnosis, and Management of Coronary No-Reflow Phenomenon.The International journal of angiology : official publication of the International College of Angiology, Inc · 2021Review
- Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: a network meta-analysis.BMC cardiovascular disorders · 2018Review
- Effect of nicorandil administration on myocardial microcirculation during primary percutaneous coronary intervention in patients with acute myocardial infarction.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2018Article
- Management standards for stable coronary artery disease in India.Indian heart journal · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, there is still a lack of an optimal treatment for no reflow phenomenon (NRP). We analyzed the efficacy and safety of using nondihydropyridine calcium channel antagonists (NDHP, verapamil/diltiazem) in patients suffering from NRP. Eight RCTs with 494 participants were eligible for analysis. The pooling analysis showed that intracoronary verapamil/diltiazem injection significantly decreased the occurrence of the coronary NRP (RR: 0.3, 95% CI: 0.16-0.57; P = 0.0002) and reduced corrected thrombolysis in myocardial infarction (TIMI) frame Count (WMD = -9.24, 95% CI -13.91-4.57; P = 0.0001) in patients with NRP. Moreover, verapamil/diltiazem treatment showed superiority in reducing wall motion index (WMI) compared to the control at day 1 (WMD = 0.11, 95% CI: 0.02-0.20; P = 0.02) (P < 0.05). There was also a significantly greater decline at occurrence of the major adverse cardiac events between verapamil/diltiazem and control groups (WMD: 0.4, 95% CI: 0.19-0.84; P = 0.02). However, using verapamil/diltiazem did not provide additional improvement of left ventricular ejection fraction post procedure (at 7 days, WMD, 0.1; 95% CI, -2.43-2.63; P = 0.94; at 30 days, WMD, 0.42; 95% CI, -2.09-2.92; P = 0.75). NDHP use is beneficial in attenuating NRP and reducing 6-month MACEs in patients with NRP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.